Exclusive Summary

• Features a unique IV (intravenous) & PO (oral) dual-formulation strategy, enabling rapid onset for acute care and seamless transition to maintenance therapy.
• Late-stage asset reaching Phase III clinical development (with US footprint indicators), offering lower R&D risk and a clearer path to commercialization compared to early-stage pipelines.
• Broad antithrombotic indications covering Ischemic Stroke, Acute Coronary Syndrome (ACS), and perioperative management for PCI, targeting a multi-billion dollar global market.